HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another Talc Cancer Jury Finds Against J&J As Claimants Line Up

This article was originally published in The Tan Sheet

Executive Summary

The $55m decision comes less than three months after a $72m finding against J&J in a similar case tried in the same St. Louis court, but this one may bode more ominously for the firm's prospects in a long line of related cases to come, plaintiff's counsel suggests.

You may also be interested in...

Talc Product Verdict Could Spur Talc-Free Powder Market Growth

J&J works to assure consumers of talc safety following a jury verdict ordering it to pay $72m in damages to the family of a woman who attributed her ovarian cancer to perineal use of the company's baby and body powders. Around 1,200 similar cases are pending against the firm in Missouri and New Jersey courts.

J&J Found Negligent In Suit Linking Talc To Cancer

While no monetary damages were awarded, a federal court jury in South Dakota found Johnson & Johnson negligent for failing to warn that talc in its body powders may be linked to cancer. However, the jury did not find that J&J’s products were defective without such a warning.

J&J Trims Formaldehyde-Releasing Chemicals In Personal Care Items

In response to consumer demand, J&J will remove controversial ingredients from both baby and adult brands, including Aveeno, Clean & Clear, Lubriderm and Neutrogena.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts